Literature DB >> 4128128

In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis.

C Webb, D Teitelbaum, R Arnon, M Sela.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4128128     DOI： 10.1002/eji.1830030506

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN： 0014-2980            Impact factor:   5.532


× No keyword cloud information.
  18 in total

Review 1.  Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

Authors:  H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

Authors:  R Aharoni; D Teitelbaum; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

3.  Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma.

Authors:  H Schori; J Kipnis; E Yoles; E WoldeMussie; G Ruiz; L A Wheeler; M Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

4.  Suppression of experimental allergic encephalomyelitis in guinea-pigs with poly-L-lysine.

Authors:  E Chelmicka-Szorc; B G Arnason
Journal:  Clin Exp Immunol       Date:  1975-12       Impact factor: 4.330

5.  Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1.

Authors:  D Teitelbaum; R Aharoni; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 6.  New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  R Arnon; M Sela; D Teitelbaum
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

7.  Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Authors:  T Ziemssen; O Neuhaus; R Hohlfeld
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

8.  A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo.

Authors:  P G Schlegel; R Aharoni; Y Chen; J Chen; D Teitelbaum; R Arnon; M Sela; N J Chao
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

Review 9.  Newer versus older treatments for relapsing-remitting multiple sclerosis.

Authors:  B Weinstock-Guttman; J A Cohen
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

10.  Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

Authors:  D Teitelbaum; R Milo; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.